One Year Study of Rifaximin Delayed Release (DR) Tablets in Crohn's Disease
Stopped The study was terminated early due to difficulty in enrollment and lack of clinical study drug access.
Conditions
Interventions
- DRUG: Rifaximin EIR
- DRUG: Placebo
Sponsor
Bausch Health Americas, Inc.
Collaborators